Presentation (CTI)

OBJECTIVES: The STEDI framework (Spectrum, Transmission, Enablement, Diversity, and Insurance value) was developed to address the value attributes of antimicrobials in health technology assessments (HTAs), recognizing that traditional cost-effectiveness analyses may underrepresent their broader societal benefits. While STEDI has gained traction in the evaluation of new antibiotics, its potential applicability to vaccines warrants exploration.
METHODS: Each STEDI dimension was systematically compared to established and emerging perspectives on vaccine value. Literature on vaccine impact and value frameworks was reviewed to identify points of alignment and divergence. The applicability and potential adaptations of each STEDI component were assessed in the context of vaccines, with special attention to unique features of vaccine interventions.
RESULTS: Analysis revealed that many STEDI value dimensions are highly relevant to the HTA of vaccines. The 'Transmission value' of vaccines is well-documented, as vaccination not only protects individuals but also reduces community transmission, a key public health benefit. 'Enablement value' is also pertinent; by preventing disease outbreaks, vaccines help ensure the continuity of healthcare services and allow for the safe delivery of routine and elective medical care. 'Diversity value' can be analogously applied to vaccine portfolio diversity, supporting system resilience against emerging or re-emerging pathogens.
A notable area of difference is 'spectrum value'. For antimicrobials, this dimension denotes the breadth of pathogen coverage, whereas vaccines have traditionally targeted specific pathogens or strains. However, recent advancements in multivalent and platform-based vaccines (e.g., mRNA technologies) are beginning to address broader coverage, suggesting that 'spectrum value' could be meaningfully adapted for vaccines.
CONCLUSIONS: The STEDI framework is largely transferable to vaccine assessment and could enhance HTA by capturing broader value elements. While certain dimensions may require adaptation, preliminary analysis supports its relevance. Further research and stakeholder input are needed to optimize its application in evaluating vaccines.